Aldeyra Therapeutics Announces First Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Aldeyra Therapeutics (ALDX) Misses Q1 EPS by 4c
May 15, 2018 7:32 AM EDTAldeyra Therapeutics (NASDAQ: ALDX) reported Q1 EPS of ($0.43), $0.04 worse than the analyst estimate of ($0.39).
"We are pleased with our progress in the first quarter, as we continued to advance our product pipeline for the treatment of immunological diseases," stated... More
